Midostaurin is an oral FLT3 and multikinase inhibitor that is approved for newly diagnosed AML with FLT3-ITD or TKD mutation and is given following intensive induction and consolidation chemotherapy on days 8–15 of a treatment cycle. The gene discussed is FLT3; the disease is acute myeloid leukemia.